Tgcbiomics

	Contact
	Téléphone : Mail : Adresse : TGCBIOMICS GMBH Postfach 4 Bingerweg 15 10042 Schweppenhausen Allemagne Web : http://www.tgcbiomics.de

	Consultez cette fiche en intégralité ?
	Consultez cette fiche et près de 50 000 autres fiches de Centres de Recherche dans plus de 30 pays européens sur Expernova.com ! Inscrivez-vous ou contactez-nous pour une démonstration personnalisée. Il s’agit de votre centre de Recherche ? Inscrivez-vous gratuitement et complétez vos informations.

	Profil scientifique partiel

	Quelques documents de Tgcbiomics
	European approach to combat outbreaks of clostridium difficult associated diarrhoea by development of new diagnostic tests EACCAD 2006 - 2009 Sujets : Medicine, Health, Life Sciences, Biotechnology Type de contrat : Specific Targeted Research Project Participants : LEIDEN UNIVERSITY MEDICAL CENTER NEDERLAND LEIDEN UNIVERSITY MEDICAL CENTER DEPARTMENT OF MEDICAL MICROBIOLOGY PO Box 9600 Albinusdreef 2 NEDERLAND ISTITUTO SUPERIORE DI SANITÀ ITALIA ISTITUTO SUPERIORE DI SANITÀ DEPARTMENT OF INFECTIOUS, PARASITIC AND IMMUNE-MEDIATED DISEASES Viale Regina Elena 299 ITALIA UNIVERSITY OF MARIBOR, MEDICAL FACULTY. SLOVENIJA UNIVERSITY OF MARIBOR, MEDICAL FACULTY. INSTITUTE FOR BIOMEDICAL RESEARCH, DEPARTMENT FOR MICROBIOLOGY AND IMMUNOLOGY Slomskov trg 15 SLOVENIJA UNIVERSITY OF NOTTINGHAM UNITED KINGDOM UNIVERSITY OF NOTTINGHAM INSTITUTE OF INFECTION, IMMUNITY & INFLAMMATION Centre for Biomolecular Sciences, University Park UNITED KINGDOM TGCBIOMICS GMBH DEUTSCHLAND TGCBIOMICS GMBH Industry TGCBIOMICS GMBH Postfach 100424 Bingerweg 15 DEUTSCHLAND CORIS BIOCONCEPT BELGIQUE-BELGIË CORIS BIOCONCEPT Industry RESEARCH & DEVELOPMENT DEPARTMENT Rue Jean Sonet, 4A BELGIQUE-BELGIË PATHOFINDER B.V. NEDERLAND PATHOFINDER B.V. PATHOFINDER B.V. Oxfordlaan 70 NEDERLAND CORIS BIOCONCEPT Belgium CORIS BIOCONCEPT Industry CORIS BIOCONCEPT R&D Crealys Park, Rue Jean Sonet 4A Belgium TGCBIOMICS Germany TGCBIOMICS Industry TGCBIOMICS GMBH Postfach 4 Bingerweg 15 Germany Hide objective Clostridium difficult-associated disease (CDAD) has become the most frequent nosocomial infection in many European hospitals, exceeding infections caused by MRSA. Its impact is considerable, both in terms of human suffering and costs of disease management. A number of factors have contributed to this escalation. On the one hand, the proportion of the European population in the principal high-risk group, the elderly, is rapidly rising. On the other, there has been a steady increase in strains exhibiting increased virulence and/or enhanced antibiotic resistance.In 2004, the situation was exacerbated by the arrival in Europe of a new hyper-virulent strain (ribotype 027) previously confined to N. America, where it has been responsible for a massive increase in CDAD incidence and associated deaths. It is imperative that an overall European strategy to combat this and similar novel variants is devised. Central to the control of epidemics are the deployment of assays able to rapidly diagnose and monitor the presence and spread of the organism. No such tests currently exist for these new hyper-virulent C. difficult strains.It is the overall objective of this proposal is to develop the urgently required rapid, diagnostic assays. Our objective will be achieved through the complementary skills of a consortium composed 3 SMEs and 4 public sector institutes, each experts in their fields. Suitable diagnostic markers (DNA- and antigen-based) will be identified using a combination of targeted approaches (focusing on toxin and antibiotic resistance determinants), and empirical approaches (DNA arrays and HT-AFLP) to identify unique strain differences. Assay development will be led by the SMEs, using proprietary technologies. Clinical validation will be performed in a certificated reference laboratory. The programme outputs will allow the formulation of a European strategy to combat the considerable threat now being posed to Europe. Source : cordis